EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacogenetic Considerations for Irinotecan Therapy

Amy Pasternak, Maisa Nazzal

SMART-MD Journal of Precision Medicine · 2024

DOI: 10.69734/1syww840 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SMART-MD Journal of Precision Medicine, 2024. Verfasst von Amy Pasternak und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacogenetic testing provides a valuable tool for personalizing irinotecan therapy, which is often used to treat pancreatic cancer, as well as many others such as colorectal cancer. Genetic variability in Uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1), which contributes to the metabolism of irinotecan, has been shown to significantly influence the risk of experiencing severe toxicity. Emerging evidence has demonstrated assessing patients for genetic variation in UGT1A1 can help to minimize adverse effects and clinical guidelines for genotype-guided irinotecan dosing are available.

Zitieren

APA

Pasternak, A., & Nazzal, M. (2024). Pharmacogenetic Considerations for Irinotecan Therapy. SMART-MD Journal of Precision Medicine. https://doi.org/10.69734/1syww840

Vancouver

Pasternak A, Nazzal M. Pharmacogenetic Considerations for Irinotecan Therapy. SMART-MD Journal of Precision Medicine. 2024. doi:10.69734/1syww840

BibTeX
@article{Pasternak2024,
  author = {Pasternak, Amy and Nazzal, Maisa},
  title = {Pharmacogenetic Considerations for Irinotecan Therapy},
  journal = {SMART-MD Journal of Precision Medicine},
  year = {2024},
  doi = {10.69734/1syww840}
}
Kostenlos starten →